Abstract
The American Diabetes Association (ADA) has presented the Standards of Medical Care in Diabetes-2024, introducing some impressive changes in description. The 2024 edition closely follows the ADA/EASD Consensus Statement. To evaluate various complications, BNP, NT-proBNP, ankle-brachial index (ABI), and the FIB-4 index are measured. The administration of SGLT2 inhibitors, GLP-1 receptor agonists, and tirzepatide is recommended for T2D adults with cardiovascular disease, heart failure (including HFrEF/HFpEF), and chronic kidney disease (CKD). For lipid control, bempedoic acid and inclisiran have been introduced. FreeStyle Libre 2 is now available, automatically sending data to the smartphone in real-time every minute.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
